BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 35086957)

  • 1. Cyst(e)inase-Rapamycin Combination Induces Ferroptosis in Both In Vitro and In Vivo Models of Hereditary Leiomyomatosis and Renal Cell Cancer.
    Kerimoglu B; Lamb C; McPherson RD; Ergen E; Stone EM; Ooi A
    Mol Cancer Ther; 2022 Mar; 21(3):419-426. PubMed ID: 35086957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cysteine depletion sensitizes prostate cancer cells to agents that enhance DNA damage and to immune checkpoint inhibition.
    Saha A; Zhao S; Kindall A; Wilder C; Friedman CA; Clark R; Georgiou G; Stone E; Kidane D; DiGiovanni J
    J Exp Clin Cancer Res; 2023 May; 42(1):119. PubMed ID: 37170264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morphologic and molecular characteristics of uterine leiomyomas in hereditary leiomyomatosis and renal cancer (HLRCC) syndrome.
    Sanz-Ortega J; Vocke C; Stratton P; Linehan WM; Merino MJ
    Am J Surg Pathol; 2013 Jan; 37(1):74-80. PubMed ID: 23211287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term response of metastatic hereditary leiomyomatosis and renal cell carcinoma syndrome associated renal cell carcinoma to bevacizumab plus erlotinib after temsirolimus and axitinib treatment failures.
    Park I; Shim YS; Go H; Hong BS; Lee JL
    BMC Urol; 2019 Jun; 19(1):51. PubMed ID: 31182090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) research.
    Ooi A
    Semin Cancer Biol; 2020 Apr; 61():158-166. PubMed ID: 31689495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hereditary leiomyomatosis and renal cell carcinoma syndrome associated uterine smooth muscle tumors: Bridging morphology and clinical screening.
    Garg K; Rabban J
    Genes Chromosomes Cancer; 2021 Mar; 60(3):210-216. PubMed ID: 33099845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete response of hereditary leiomyomatosis and renal cell cancer (HLRCC)-associated renal cell carcinoma to nivolumab and ipilimumab combination immunotherapy by: a case report.
    Iribe Y; Furuya M; Shibata Y; Yasui M; Funahashi M; Ota J; Iwashita H; Nagashima Y; Hasumi H; Hayashi N; Makiyama K; Kondo K; Tanaka R; Yao M; Nakaigawa N
    Fam Cancer; 2021 Jan; 20(1):75-80. PubMed ID: 32666341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combinatorial Approaches to Enhance DNA Damage following Enzyme-Mediated Depletion of L-Cys for Treatment of Pancreatic Cancer.
    Saha A; Zhao S; Chen Z; Georgiou G; Stone E; Kidane D; DiGiovanni J
    Mol Ther; 2021 Feb; 29(2):775-787. PubMed ID: 33091613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal cell carcinoma in young FH mutation carriers: case series and review of the literature.
    Hol JA; Jongmans MCJ; Littooij AS; de Krijger RR; Kuiper RP; van Harssel JJT; Mensenkamp A; Simons M; Tytgat GAM; van den Heuvel-Eibrink MM; van Grotel M
    Fam Cancer; 2020 Jan; 19(1):55-63. PubMed ID: 31792767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hereditary Leiomyomatosis and Renal Cell Cancer: Clinical, Molecular, and Screening Features in a Cohort of 185 Affected Individuals.
    Forde C; Lim DHK; Alwan Y; Burghel G; Butland L; Cleaver R; Dixit A; Evans DG; Hanson H; Lalloo F; Oliveira P; Vialard L; Wallis Y; Maher ER; Woodward ER
    Eur Urol Oncol; 2020 Dec; 3(6):764-772. PubMed ID: 31831373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fumarate hydratase as a therapeutic target in renal cancer.
    Kancherla P; Daneshvar M; Sager RA; Mollapour M; Bratslavsky G
    Expert Opin Ther Targets; 2020 Sep; 24(9):923-936. PubMed ID: 32744123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hereditary leiomyomatosis syndrome associated with renal cell carcinoma. A case report].
    González Ibáñez MV; Ruiz Cabezas L; Moreno Ontalba A; Rubio Fernández A; Mayoral Guisado C; Flores Barranquero M; Díaz Delgado M
    Rev Esp Patol; 2021; 54(3):193-196. PubMed ID: 34175032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteasome inhibition disrupts the metabolism of fumarate hydratase- deficient tumors by downregulating p62 and c-Myc.
    Sourbier C; Ricketts CJ; Liao PJ; Matsumoto S; Wei D; Lang M; Railkar R; Yang Y; Wei MH; Agarwal P; Krishna M; Mitchell JB; Trepel JB; Neckers L; Linehan WM
    Sci Rep; 2019 Dec; 9(1):18409. PubMed ID: 31804603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of prospective pathologic evaluation to inform clinical genetic testing for hereditary leiomyomatosis and renal cell carcinoma.
    Kopp RP; Stratton KL; Glogowski E; Schrader KA; Rau-Murthy R; Russo P; Coleman JA; Offit K
    Cancer; 2017 Jul; 123(13):2452-2458. PubMed ID: 28171700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hereditary leiomyomatosis and renal cell carcinoma (HLRCC): a rapid autopsy report of metastatic renal cell carcinoma.
    Udager AM; Alva A; Chen YB; Siddiqui J; Lagstein A; Tickoo SK; Reuter VE; Chinnaiyian AM; Mehra R
    Am J Surg Pathol; 2014 Apr; 38(4):567-77. PubMed ID: 24625422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD8
    Wang W; Green M; Choi JE; Gijón M; Kennedy PD; Johnson JK; Liao P; Lang X; Kryczek I; Sell A; Xia H; Zhou J; Li G; Li J; Li W; Wei S; Vatan L; Zhang H; Szeliga W; Gu W; Liu R; Lawrence TS; Lamb C; Tanno Y; Cieslik M; Stone E; Georgiou G; Chan TA; Chinnaiyan A; Zou W
    Nature; 2019 May; 569(7755):270-274. PubMed ID: 31043744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth.
    Cramer SL; Saha A; Liu J; Tadi S; Tiziani S; Yan W; Triplett K; Lamb C; Alters SE; Rowlinson S; Zhang YJ; Keating MJ; Huang P; DiGiovanni J; Georgiou G; Stone E
    Nat Med; 2017 Jan; 23(1):120-127. PubMed ID: 27869804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hereditary leiomyomatosis and renal cell cancer (HLRCC).
    Kiuru M; Launonen V
    Curr Mol Med; 2004 Dec; 4(8):869-75. PubMed ID: 15579034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increasing reactive oxygen species as a therapeutic approach to treat hereditary leiomyomatosis and renal cell carcinoma.
    Sourbier C; Valera-Romero V; Giubellino A; Yang Y; Sudarshan S; Neckers L; Linehan WM
    Cell Cycle; 2010 Oct; 9(20):4183-9. PubMed ID: 20953139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cell carcinoma: Morphological appraisal with a comprehensive review of differential diagnoses.
    El-Zaatari Z; Divatia MK
    Indian J Pathol Microbiol; 2020 Feb; 63(Supplement):S7-S17. PubMed ID: 32108620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.